Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Notalgia Paresthetica (NP) is a sensory neuropathy marked by localised itching and pain, which may or may not be accompanied by a distinct hyperpigmented patch on the upper back. Here are some DIY ...

Corporate Restructuring and Strategic Focus In January 2024, Cara Therapeutics underwent a significant corporate restructuring, narrowing its focus to the development of oral difelikefalin (DFK) for ...

Cara Therapeutics said its Notalgia Paresthetica drug failed in clinical trials. The company is looking at strategic alternatives. Feel unsure about the market’s next move? Copy trade alerts ...

CARA THERAPEUTICS INC WKN: A1XDTK|ISIN: US1407551092|Ticker-Symbol: 69C Tradegate 20.12.24 18:16 0,411Euro +0,014+3,42 % Nachrichten Analysen Kurse Chart Branche Biotechnologie Aktienmarkt ...

– Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics (CARA), Inc. , a development-stage ...

STAMFORD, Conn. - Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on pruritus treatments, has announced the discontinuation of its clinical program for notalgia ...

Cara Therapeutics said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its oral drug did not show meaningful clinical benefit ...

Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024 PRESS RELEASE GlobeNewswire Mar. 7, 2024, 07:00 AM ...

Notalgia paresthetica is an unexplored neuropathy, and yet NP is relatively common. The disease is a chronic neuropathic pruritic condition characterized by pruritus of the upper back, often leading ...